WPNOW

Trending Topics

Loading trending topics...

Heatmap
About UsNews SourcesSubscribeMobileContact UsPrivacy Policy
© 2025 World Pulse Now
See what’s trending right now
Asian tradein Financial Markets
4 hours ago

China's credit demand surges with June yuan loans exceeding forecasts, supported by seasonal factors and bond sales, while Synopsys gains conditional approval to acquire Ansys, signaling regulatory openness.

HomeFinancial Markets

India-US trade deal: Opening India’s dairy sector to America could cause huge losses; 'Rs 1.03 lakh crore annually…’

Times of IndiaMonday, July 14, 2025 at 6:28:12 AM
NegativeFinancial MarketsTrade Policy
India-US trade deal: Opening India’s dairy sector to America could cause huge losses; 'Rs 1.03 lakh crore annually…’
India is pushing back against opening its dairy and agriculture markets to the U.S. in ongoing trade talks, worried it could devastate local farmers. A State Bank of India report warns that allowing American dairy imports might cost India’s domestic industry a staggering ₹1.03 lakh crore per year—a massive hit to a sector that’s crucial for rural livelihoods.
Editor’s Note: This isn’t just about milk—it’s about protecting millions of small farmers who rely on dairy for survival. The U.S. has long wanted greater access to India’s agricultural markets, but India’s resistance shows how trade deals can pit economic growth against local vulnerability. If the government caves, it could reshape rural economies overnight. If it doesn’t, it might stall a broader trade agreement with strategic implications. Either way, farmers are caught in the middle.
— Curated via WP Now’s
Read Original

Was this article worth reading? Share it

Latest from Financial Markets
H.C. Wainwright maintains Buy rating on Abeona Therapeutics stock despite FDA setback
Investing.com23 minutes ago
H.C. Wainwright maintains Buy rating on Abeona Therapeutics stock despite FDA setback
NeutralFinancial Markets
Analyst firm H.C. Wainwright is sticking with its "Buy" recommendation for Abeona Therapeutics, even after the FDA rejected one of the company's key treatments. The firm seems confident Abeona can bounce back, suggesting this setback might just be a temporary hurdle rather than a dealbreaker.
Editor’s Note: For investors watching Abeona, this is a signal that not all hope is lost. FDA rejections can tank biotech stocks, but when analysts keep the faith, it often means there’s a path forward—maybe revised data, better trials, or a different approach. If you’re into high-risk, high-reward plays, this kind of resilience could be worth keeping an eye on.
Read full article
via Investing.com
Stoke Therapeutics stock maintains Buy rating at H.C. Wainwright on positive study data
Investing.com23 minutes ago
Stoke Therapeutics stock maintains Buy rating at H.C. Wainwright on positive study data
PositiveFinancial Markets
Stoke Therapeutics got a vote of confidence from analysts at H.C. Wainwright, who are keeping their "Buy" rating on the stock after the company shared encouraging results from a recent study. Basically, the data looks promising enough that experts think the stock is still a good bet.
Editor’s Note: For investors tracking biotech, this is a sign that Stoke’s research might be on the right track—enough to keep Wall Street interested. Positive analyst ratings can sway market sentiment, so it’s worth watching how this plays out for the company’s stock and future trials.
Read full article
via Investing.com
Melius initiates coverage on Wingstop stock with Hold rating
Investing.com24 minutes ago
Melius initiates coverage on Wingstop stock with Hold rating
NeutralFinancial Markets
Investment firm Melius has started covering Wingstop's stock, slapping it with a "Hold" rating—basically saying "don't buy more, but don’t sell what you’ve got either." It’s a lukewarm take, suggesting they see the chicken chain as steady but not exactly poised for a breakout.
Editor’s Note: For investors, this kind of analyst coverage is like getting a weather report—it doesn’t tell you whether to cancel the picnic, but it helps you decide if you should bring an umbrella. Wingstop’s been a strong performer lately, so a "Hold" might signal that the hype’s cooled off, and it’s time to wait and see. For the rest of us? Just a reminder that even buffalo wings have a stock price.
Read full article
via Investing.com
Dianthus Therapeutics stock awaits key September data in Myasthenia Gravis
Investing.com24 minutes ago
Dianthus Therapeutics stock awaits key September data in Myasthenia Gravis
NeutralFinancial Markets
Investors and patients with Myasthenia Gravis (a rare autoimmune disorder) are keeping a close eye on Dianthus Therapeutics this September. The biotech company is set to release critical clinical trial data for its experimental treatment—a make-or-break moment that could send its stock soaring or sinking, depending on the results.
Editor’s Note: For folks battling Myasthenia Gravis, new treatments are hard to come by, so promising data could mean real hope. For investors, it’s a high-stakes gamble—positive results might turn Dianthus into a hot stock overnight, while disappointing numbers could spell trouble. Either way, September’s update is a big deal for both Wall Street and the patient community.
Read full article
via Investing.com
H.C. Wainwright slashes Capricor stock price target to $24 on FDA rejection
Investing.com24 minutes ago
H.C. Wainwright slashes Capricor stock price target to $24 on FDA rejection
NegativeFinancial Markets
Investment firm H.C. Wainwright just took a hatchet to its price target for Capricor Therapeutics, cutting it from $35 to $24 after the FDA rejected the biotech company's treatment. It's a tough blow for Capricor, signaling regulators aren't convinced by their data—at least not yet.
Editor’s Note: FDA rejections always sting, but this one hits investors doubly hard with a major downgrade from a key analyst. For biotech watchers, it’s a reminder of how risky these stocks can be—one regulatory decision can send shockwaves through a company’s valuation overnight. Capricor now has to regroup and figure out its next move.
Read full article
via Investing.com

Why World Pulse Now?

Global Coverage

All major sources, one page

Emotional Lens

Feel the mood behind headlines

Trending Topics

Know what’s trending, globally

Read Less, Know More

Get summaries. Save time

Stay informed, save time
Learn more

Live Stats

Articles Processed

7,427

Trending Topics

116

Sources Monitored

204

Last Updated

13 minutes ago

Live data processing
How it works

Mobile App

Available on iOS & Android

The mobile app adds more ways to stay informed — including offline reading, voice-enabled summaries, and personalized trend alerts.

Get it on Google PlayDownload on the App Store
Available now on iOS and Android

1-Minute Daily Briefing

Stay sharp in 60 seconds. Get concise summaries of today’s biggest stories — markets, tech, sports, and more

By subscribing, you agree to our Privacy Policy